RP
Rhythm Pharmaceuticals
Biopharmaceutical company focused on rare genetic diseases of obesity.
Rate
About
Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare genetic diseases of obesity. Their lead product, IMCIVREE (setmelanotide), is approved in the U.S. and Europe for specific genetic forms of obesity.
Technology stack
detected 2026-06-09Est. monthly stack spend~$70/mo
Email
Microsoft 365
Comments
No comments yet. Be the first to share your take.
Frequently asked
What does Rhythm Pharmaceuticals do?
Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare genetic diseases of obesity. Their lead product, IMCIVREE (setmelanotide), is approved in the U.S. and Europe for specific genetic forms of obesity.
Where is Rhythm Pharmaceuticals headquartered?
Rhythm Pharmaceuticals is headquartered in Boston, United States.
When was Rhythm Pharmaceuticals founded?
Rhythm Pharmaceuticals was founded in 2008.
What industry does Rhythm Pharmaceuticals operate in?
Rhythm Pharmaceuticals operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials, Rare Diseases.
What is Rhythm Pharmaceuticals's current status?
Rhythm Pharmaceuticals's current operating status is: Inactive.